Adocia Sa · EURONEXT:ADOC
Adocia Sa — Investor Presentation (June 2017)
32 slides from Adocia Sa's investor presentation, June 2017
Slide 1: Corporate Presentation June 2017
CORPORATE PRESENTATION JUNE 2017
Slide 2: Disclaimer
INTRO Disclaimer This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying t
Slide 3: Our mission is dedicated to the treatment of diabetes
ADOCIA Our mission is dedicated to the treatment of diabetes Provide people with more physiologic treatments of diabetes in a simple and affordable way to help them avoid severe consequences of their disease June 2017 3
Slide 4: Management Team
ADOCIA Management Team Gérard Soula Olivier Soula Valérie Danaguezian Rémi Soula Steve Daly PhD, MBA PhD, MBA PhD, MBA President & CEO Deputy General Manager, Chief Financial Officer Director of BD & IP US General Manager Co-founder R&D Director Co-founder Co-founder June 2017 4
Slide 5: ADOCIA in summary
ADOCIA ADOCIA in summary 1 Large portfolio of next-generation injectables for diabetes treatment 2 Business model leveraging already-approved proteins, enhanced with BioChaperone® 3 New generation products BC Lispro & BC Combo 4 First-in-class BC Prandial Combinations 5 Preclinical and early clinica
Slide 6: Current portfolio addresses the diverse medical needs of diabetes patient populations
ADOCIA Current portfolio addresses the diverse medical needs of diabetes patient populations In vitro PC Phase I/II Phase III In vitro PC Phase I/II BC Lispro U100 BC Glucagon BC Lispro U200 BC Gla GLP-1 BC Combo (BC Gla Lis) BC Lis Pram HinsBet U100 BC Lis Exe HinsBet U500 Supported by a Top-Tier M
Slide 7: There remains a real medical need in diabetes
DIABETES There remains a real medical need in diabetes 26M2 on insulin 415M1 people with ▪ Despite 100 years of medical treatment, long-term diabetes in 2015 consequences of diabetes remain a major issue ▪ There is a need to address the underlying complexity of diabetes 79%3 ▪ With more granularity
Slide 8: 3 pillars support the future of diabetes treatment
DIABETES 3 pillars support the future of diabetes treatment More physiologic approaches ▪ Ultra-rapid insulin action ▪ Combo of synergistic hormones [BioChaperone® Hormone] Complex Affordability Patient engagement ▪ Leverage approved hormones ▪ Enable simple treatments vs. NCE development June 2017
Slide 9: BioChaperone unlocks the potential of hormones and their combinations in a cost-effective way
ADOCIA BioChaperone® unlocks the potential of hormones and their combinations in a cost-effective way BioChaperone® Hormones (library of molecules) (insulin, GLP-1 RA, amylin, glucagon) [BioChaperone® Hormone] Complex ✓ Accelerated absorption ✓Improved solubility ✓Improved stability 32 patent famili
Slide 10: BioChaperone Insulin Clinical Programs
BIOCHAPERONE INSULIN CLINICAL PROGRAMS June 2017 10
Slide 11: BC Lispro: A more physiologic ultra-rapid insulin for better outcomes
BC LISPRO A more physiologic ultra-rapid insulin for better outcomes ▪ Ultra-rapid insulin is a new class of prandial insulins – 1st approved product is $7B Novo Nordisk Fiasp® (Europe, Canada) Prandial ▪ Introduced at price parity with Novolog® insulin market (2016)1 ▪ We expect ultra-rapid insulin
Slide 12: BC Lispro improves glycemic control vs. analogs
BC LISPRO BC Lispro improves glycemic control vs. analogs Post-meal glycaemia in T1D ▪ Accelerated absorption and better post-prandial control for BC Lispro U100 vs. Humalog observed AUC0-2h: across T1D & T2D patients & devices -61%* ▪ Consistent results obtained in 210 people with T1D & T2D across
Slide 13: BC Combo: A safer and more efficient alternative to premixed insulin
BC COMBO A safer and more efficient alternative to premixed insulin for the treatment of T2D ▪ Combinations of basal and prandial insulins are a new generation of 2-in-1 insulin $5B intensification for type 2 diabetes Premix insulin ▪ 1st in class is Novo Nordisk Ryzodeg® (insulin degludec+aspart; a
Slide 14: BC Combo has shown superior prandial and basal control compared to premix insulin
BC COMBO BC Combo has shown superior prandial and basal control compared to premix insulin Post-meal glycemia in T1D ▪ 4 successful Phase 1/2 clinical studies (2 in T1D & 2 in T2D)(1,2) ▪ In T1D & T2D BC Combo showed superiority vs. Humalog Mix25 (1,2): Individualized doses ✓ Less hyperglycemia (fas
Slide 15: HinsBet: Affordable prandial insulin for price-sensitive populations
HINSBET Affordable prandial insulin for price-sensitive populations ▪ HinsBet is a formulation of human insulin designed to act as rapidly as an insulin analog $1B ▪ 77% of people with diabetes live in low- and middle-income countries Human prandial ▪ For economic reasons, human insulin is the most
Slide 16: HinsBet displays similar early action to fast-acting insulin analog in T1D patients
HINSBET HinsBet displays similar early action to fast-acting insulin analog in T1D patients Early Glucose Infusion Rate (U100)1 ▪ Meal-test study in 36 T1D confirmed PD profile in first hour2 (Oct 2016) ▪ During first hour after the meal, HinsBet: ✓ 70% earlier onset ▪ Significantly reduced glucose
Slide 17: New Programs
NEW PROGRAMS June 2017 7 ADOCIA f-
Slide 18: How to potentialize insulin action?
MULTI- HORMONAL How to potentialize insulin action? In combination BC Glargine GLP-1 Efficacy GLP-1 Amylin BC Lispro Pramlintide Insulin BC Lispro Exenatide In a dual-chamber pump Safety Glucagon BC Glucagon + Insulin June 2017 18
Slide 19: In healthy people, a time-sensitive hormonal pattern maintains normoglycemia
DIABETES In healthy people, a time-sensitive hormonal pattern maintains normoglycemia Schematic representation of hormonal pattern1 Insulin Healthy With Type 1 diabetes (T1D) Level of secretion Amylin (relative scale) Glucagon GLP-1 GLP-1 Glucagon Insulin Amylin 0 1 2 3 4 5 6 0 1 2 3 4 5 6 Time Meal
Slide 20: BC Glucagon: A ready-to-use aqueous formulation of human glucagon
BC A ready-to-use aqueous formulation of human GLUCAGON glucagon for acute and chronic use ▪ Ready-to-use glucagon products should unlock its full therapeutic potential ▪ Poor usability of current lyophilized rescue kits to treat severe hypoglycemia ▪ Liquid ready-to-use formulations are needed for
Slide 21: Promising preclinical results support first-in-man study
BC GLUCAGON Promising preclinical results support first-in-man study ▪ BC Human Glucagon showed similar action on Mean blood glucose (pigs) blood glucose compared to Glucagen® HypoKit ® during the first 3 hours in preclinical studies ▪ BC Human Glucagon is soluble and stable at pH 7 Glucose (mg/dL)
Slide 22: BC Prandial Combos: Enabling prandial insulin-based multi-hormonal treatment
BC PRANDIAL Enabling prandial insulin-based multi-hormonal treatment COMBOS to improve long-term outcomes in T1D ▪ Tighter glycemic control lowers the risk of severe complications1, and insulin alone, while life-saving, is insufficient to prevent long-term complications ▪ Multiple hormonal combinati
Slide 23: Leveraging the clinically proven benefits of co-administering prandial insulin with other hormones
BC PRANDIAL Leveraging the clinically proven benefits of co-administering COMBOS prandial insulin with other metabolic hormones Change in prandial Change in weight insulin dose after 6 after 6 months (kg) months (%) 0 ▪ Pramlintide TID has demonstrated synergistic benefit when 0 administered with pr
Slide 24: BC GLAR GLP-1: Efficient and affordable intensification options over basal insulin for T2D
BC Efficient and affordable intensification options over GLAR GLP-1 basal insulin for T2D $7B1 ▪ Combinations of basal insulin and GLP-1 are a new class of treatment for T2D Forecasted ▪ 50% patients are not controlled on basal insulin alone2 Basal-GLP1 ▪ 2 products recenty approved in EU & US for T
Slide 25: Key financial elements
ADOCIA Key financial elements Financial summary Shareholders’ equity (May, 2017) Analysts ▪ Listed on Euronext Paris (ADOC) Free Float (*) Soula Family 22.1 % ▪ Leerink (Seamus Fernandez) 60.9% ▪ Jefferies (Peter Welford) ▪ 6.9M shares outstanding ▪ Kepler Market (Arsène Guekam) ▪ Invest Securities
Slide 26: Expected upcoming catalysts
ADOCIA Expected upcoming catalysts Clinical programs Preclinical programs ▪ BC LISPRO ▪ BC LISPRO PRAMLINTIDE & ▪ Phase 3-ready asset to be partnered BC LISPRO EXENATIDE ▪ Ongoing Phase 1b trial vs. Fiasp®: results expected Q4 17 ▪ First-in-man study : 2017 ▪ BC COMBO ▪ Ongoing dose-response study i
Slide 27: Thank you for your kind interest
THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 [email protected] June 2017 27
Slide 28: Appendix
APPENDIX June 2017 28 ADOCIA f-
Slide 29: Adocia is supported by a top-tier Medical Advisory Board
ADOCIA Adocia is supported by a top-tier Medical Advisory Board ▪ 12 highly renowned international thought-leaders: ▪ Dr. Jay Skyler, MD, Chairman, University of Miami (US) ▪ Dr. Vanita Aroda, MD, MedStar Health Research Institute (US) ▪ Dr. Bruce Bode, MD, Emory University (US) ▪ Dr. John Buse, MD,
Slide 30: BC Lispro: Results summary compared to Humalog U100 in T1DM subjects
BC LISPRO Results summary compared to Humalog U100 in T1DM subjects 294-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Biochaperone Lispro: Shorter TMAX, Higher CMAX ▪ BioChaperone Lispro in comparison with and Similar Exposure Greater Earlier Exposure: Faster In Humalo
Slide 31: BC Combo: Results summary compared to Conventional Lispro Mix 75/25 in T1DM subjects
BC COMBO Results summary compared to Conventional Lispro Mix 75/25 in T1DM subjects 295-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Mean Unadjusted BG Profiles ± SEM Over 6hr After s.c. Cumulative Percentage of Subjects With BG Values < 63 mg/dL ▪ In this solid mixed
Slide 32: BC Combo: Results summary compared to Humalog 75/25 in T2DM subjects
BC COMBO Results summary compared to Humalog 75/25 in T2DM subjects 942-P in 12-B Clinical Therapeutics/ New Technology-Insulins, June 11, 2016, 76th ADA Scientific Sessions Smoothed GIR Profiles (0-30h) of 0.8 U/kg BioChaperone Combo, 0.8 Smoothed GIR Profiles (0-2h) of 0.8 U/kg BioChaperone ▪ In t